Cefaclor
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00833 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 17 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | polyclonal hyperviscosity syndrome | KG + DL |
| 2 | hyperamylasemia | KG + DL |
| 3 | gonococcal urethritis | KG + DL |
| 4 | Ureaplasma urethritis | KG + DL |
| 5 | congenital analbuminemia | KG + DL |
| 6 | blood group incompatibility | KG + DL |
| 7 | uterine inflammatory disease | KG + DL |
| 8 | xanthogranulomatous pyelonephritis | KG + DL |
| 9 | premalignant hematological system disease | KG + DL |
| 10 | monoclonal gammopathy | KG + DL |
| 11 | hematological disease associated with an acquired peripheral neuropathy | KG + DL |
| 12 | septicemic plague | KG + DL |
| 13 | congenital hematological disorder | KG + DL |
| 14 | bronchitis | KG + DL |
| 15 | laryngotracheitis | KG + DL |
| 16 | hematopoietic and lymphoid system neoplasm | KG + DL |
| 17 | bubonic plague | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.